Centessa Pharmaceuticals
Executives
View the org chart displaying its 19 main executives
Most searched biographies at Centessa Pharmaceuticals
- Saurabh Saha, Chief Executive Officer and Director
- Francesco De Rubertis, Chairman of The Board
- Mary Hedley, Director
Popular executive movements at Centessa Pharmaceuticals
- Ellie Im has joined the company as Senior Vice President of Clinical Development, Oncology (posted on October 3 2023).
- April Dovholuk has joined the company as Senior Vice President of Development Operations (posted on October 3 2023).
Create your alert
to follow the executive moves at Centessa Pharmaceuticals.
Pharmaceuticals
Centessa Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day | Centessa Pharmaceuticals
- View more press releases Close
Social media about Centessa Pharmaceuticals
- Centessa Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Centessa Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Saurabh Saha 
Call Centessa Pharmaceuticals at +1 857...
